APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Analysis and Forecast 2026-2032

31 December 2025198 pages

Choose your research edition.

Industry ResearchVancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections include Eli Lily, Wockhardt Ltd, Therapeutic Systems Research Laboratories Inc, TGV-Inhalonix Inc, Roivant Sciences Ltd, Lysimmune BioScience, Destiny Pharma Plc, Debiopharm International SA and CrystalGenomics Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections, also provides the sales of main regions and countries. Of the upcoming market potential for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections sales, projected growth trends, production technology, application and end-user industry.

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Company

Eli Lily

Wockhardt Ltd

Therapeutic Systems Research Laboratories Inc

TGV-Inhalonix Inc

Roivant Sciences Ltd

Lysimmune BioScience

Destiny Pharma Plc

Debiopharm International SA

CrystalGenomics Inc

Amprologix Ltd

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Type

Injection

Pills

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Application

Hospital

Clinic

Other

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Injection Major Manufacturers Table 3. Pills Major Manufacturers Table 4. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Manufacturers Table 6. Clinic Major Manufacturers Table 7. Other Major Manufacturers Table 8. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Trends Table 9. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Drivers Table 10. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Opportunities and Challenges Table 11. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Restraints Table 12. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Region (2021-2026) Table 16. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Region (2027-2032) Table 17. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region (2021-2026) & (K Units) Table 19. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region (2027-2032) & (K Units) Table 20. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Region (2021-2026) Table 21. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Region (2027-2032) Table 22. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Manufacturers (2021-2026) Table 26. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Manufacturers, Product Type & Application Table 30. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Type (2021-2026) Table 37. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Type (2027-2032) Table 38. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (K Units) Table 40. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2027-2032) & (K Units) Table 41. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Type (2021-2026) Table 42. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Type (2027-2032) Table 43. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Type (2021-2026) & (US$/Unit) Table 44. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Type (2027-2032) & (US$/Unit) Table 45. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Application (2021-2026) Table 49. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Application (2027-2032) Table 50. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (K Units) Table 52. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2027-2032) & (K Units) Table 53. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Application (2021-2026) Table 54. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Application (2027-2032) Table 55. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Application (2021-2026) & (US$/Unit) Table 56. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Application (2027-2032) & (US$/Unit) Table 57. Eli Lily Company Information Table 58. Eli Lily Business Overview Table 59. Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 61. Eli Lily Recent Development Table 62. Wockhardt Ltd Company Information Table 63. Wockhardt Ltd Business Overview Table 64. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 66. Wockhardt Ltd Recent Development Table 67. Therapeutic Systems Research Laboratories Inc Company Information Table 68. Therapeutic Systems Research Laboratories Inc Business Overview Table 69. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 71. Therapeutic Systems Research Laboratories Inc Recent Development Table 72. TGV-Inhalonix Inc Company Information Table 73. TGV-Inhalonix Inc Business Overview Table 74. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 76. TGV-Inhalonix Inc Recent Development Table 77. Roivant Sciences Ltd Company Information Table 78. Roivant Sciences Ltd Business Overview Table 79. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 81. Roivant Sciences Ltd Recent Development Table 82. Lysimmune BioScience Company Information Table 83. Lysimmune BioScience Business Overview Table 84. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 86. Lysimmune BioScience Recent Development Table 87. Destiny Pharma Plc Company Information Table 88. Destiny Pharma Plc Business Overview Table 89. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 91. Destiny Pharma Plc Recent Development Table 92. Debiopharm International SA Company Information Table 93. Debiopharm International SA Business Overview Table 94. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 96. Debiopharm International SA Recent Development Table 97. CrystalGenomics Inc Company Information Table 98. CrystalGenomics Inc Business Overview Table 99. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 101. CrystalGenomics Inc Recent Development Table 102. Amprologix Ltd Company Information Table 103. Amprologix Ltd Business Overview Table 104. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 106. Amprologix Ltd Recent Development Table 107. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021-2026) & (US$ Million) Table 108. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2027-2032) & (US$ Million) Table 109. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (K Units) Table 110. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2027-2032) & (K Units) Table 111. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Type (2021-2026) & (US$/Unit) Table 112. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Type (2027-2032) & (US$/Unit) Table 113. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021-2026) & (US$ Million) Table 114. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2027-2032) & (US$ Million) Table 115. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (K Units) Table 116. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2027-2032) & (K Units) Table 117. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Application (2021-2026) & (US$/Unit) Table 118. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Application (2027-2032) & (US$/Unit) Table 119. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 121. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 122. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 123. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026) & (K Units) Table 124. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2027-2032) & (K Units) Table 125. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Country (2021-2026) & (US$/Unit) Table 126. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Country (2027-2032) & (US$/Unit) Table 127. United States Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 128. Canada Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 129. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021-2026) & (US$ Million) Table 130. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2027-2032) & (US$ Million) Table 131. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (K Units) Table 132. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2027-2032) & (K Units) Table 133. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Type (2021-2026) & (US$/Unit) Table 134. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Type (2027-2032) & (US$/Unit) Table 135. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021-2026) & (US$ Million) Table 136. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2027-2032) & (US$ Million) Table 137. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (K Units) Table 138. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2027-2032) & (K Units) Table 139. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Application (2021-2026) & (US$/Unit) Table 140. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Application (2027-2032) & (US$/Unit) Table 141. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 143. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 144. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 145. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026) & (K Units) Table 146. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2027-2032) & (K Units) Table 147. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Country (2021-2026) & (US$/Unit) Table 148. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Country (2027-2032) & (US$/Unit) Table 149. Germany Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 150. France Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 151. U.K. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 152. Italy Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 153. Netherlands Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 154. Nordic Countries Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 155. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021-2026) & (US$ Million) Table 156. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2027-2032) & (US$ Million) Table 157. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (K Units) Table 158. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2027-2032) & (K Units) Table 159. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Type (2021-2026) & (US$/Unit) Table 160. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Type (2027-2032) & (US$/Unit) Table 161. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021-2026) & (US$ Million) Table 162. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2027-2032) & (US$ Million) Table 163. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (K Units) Table 164. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2027-2032) & (K Units) Table 165. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Application (2021-2026) & (US$/Unit) Table 166. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Application (2027-2032) & (US$/Unit) Table 167. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021-2026) & (US$ Million) Table 168. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2027-2032) & (US$ Million) Table 169. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (K Units) Table 170. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2027-2032) & (K Units) Table 171. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Type (2021-2026) & (US$/Unit) Table 172. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Type (2027-2032) & (US$/Unit) Table 173. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021-2026) & (US$ Million) Table 174. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2027-2032) & (US$ Million) Table 175. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (K Units) Table 176. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2027-2032) & (K Units) Table 177. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Application (2021-2026) & (US$/Unit) Table 178. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Application (2027-2032) & (US$/Unit) Table 179. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 180. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 181. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 182. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 183. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026) & (K Units) Table 184. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2027-2032) & (K Units) Table 185. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Country (2021-2026) & (US$/Unit) Table 186. Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Country (2027-2032) & (US$/Unit) Table 187. Japan Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 188. South Korea Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 189. India Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 190. Australia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 191. China Taiwan Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 192. Southeast Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 193. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021-2026) & (US$ Million) Table 194. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2027-2032) & (US$ Million) Table 195. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (K Units) Table 196. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2027-2032) & (K Units) Table 197. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Type (2021-2026) & (US$/Unit) Table 198. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Type (2027-2032) & (US$/Unit) Table 199. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021-2026) & (US$ Million) Table 200. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2027-2032) & (US$ Million) Table 201. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (K Units) Table 202. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2027-2032) & (K Units) Table 203. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Application (2021-2026) & (US$/Unit) Table 204. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Application (2027-2032) & (US$/Unit) Table 205. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 206. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 207. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 208. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 209. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026) & (K Units) Table 210. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2027-2032) & (K Units) Table 211. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Country (2021-2026) & (US$/Unit) Table 212. SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Country (2027-2032) & (US$/Unit) Table 213. Brazil Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 214. Argentina Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 215. Chile Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 216. Colombia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 217. Peru Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 218. Saudi Arabia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 219. Israel Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 220. UAE Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 221. Turkey Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 222. Iran Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 223. Egypt Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Table 224. Key Raw Materials Table 225. Raw Materials Key Suppliers Table 226. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Distributors List Table 227. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Customers List Table 228. Research Programs/Design for This Report Table 229. Authors List of This Report Table 230. Secondary Sources Table 231. Primary Sources List of Figures Figure 1. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Image Figure 2. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Share 2021 VS 2025 VS 2032 Figure 4. Injection Image Figure 5. Pills Image Figure 6. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Other Image Figure 11. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2032) & (US$ Million) Figure 13. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Region (2021-2032) Figure 16. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (2021-2032) & (K Units) Figure 17. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales YoY (2021-2032) & (K Units) Figure 20. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales YoY (2021-2032) & (K Units) Figure 21. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales YoY (2021-2032) & (K Units) Figure 24. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Type (2021-2032) Figure 30. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Type (2021-2032) Figure 33. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Application (2021-2032) Figure 36. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Application (2021-2032) Figure 39. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Share by Type (2021-2032) Figure 40. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Share by Type (2021-2032) Figure 41. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Share by Application (2021-2032) Figure 42. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Share by Application (2021-2032) Figure 43. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Share by Country (2021-2032) Figure 44. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Share by Country (2021-2032) Figure 45. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Share by Type (2021-2032) Figure 46. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Share by Type (2021-2032) Figure 47. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Share by Application (2021-2032) Figure 48. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Share by Application (2021-2032) Figure 49. Europe Vancomycin-Resistant Staph

Scope & coverage.

Types
  • Injection
  • Pills
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Eli Lily
  • Wockhardt Ltd
  • Therapeutic Systems Research Laboratories Inc
  • TGV-Inhalonix Inc
  • Roivant Sciences Ltd
  • Lysimmune BioScience
  • Destiny Pharma Plc
  • Debiopharm International SA
  • CrystalGenomics Inc
  • Amprologix Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market by Type
  3. 1.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Injection
  5. 1.2.3 Pills
  6. 1.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market by Application
  7. 1.3.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Dynamics
  1. 2.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Trends
  2. 2.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Drivers
  3. 2.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Opportunities and Challenges
  4. 2.4 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Region
  3. 3.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Region (2021-2026)
  5. 3.2.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Region (2027-2032)
  6. 3.2.4 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region
  9. 3.4.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region (2021-2026)
  11. 3.4.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region (2027-2032)
  12. 3.4.4 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Manufacturers
  2. 4.1.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Manufacturers
  6. 4.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Manufacturers, Product Type & Application
  13. 4.7 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market CR5 and HHI
  16. 4.8.2 2025 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Tier 1, Tier 2, and Tier 3
5 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market by Type
  1. 5.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type
  2. 5.1.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type
  6. 5.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Type (2021-2032)
  9. 5.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Type
6 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market by Application
  1. 6.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application
  2. 6.1.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application
  6. 6.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Application (2021-2032)
  9. 6.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Application
7 Company Profiles
  1. 7.1 Eli Lily
  2. 7.1.1 Eli Lily Company Information
  3. 7.1.2 Eli Lily Business Overview
  4. 7.1.3 Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  6. 7.1.5 Eli Lily Recent Developments
  7. 7.2 Wockhardt Ltd
  8. 7.2.1 Wockhardt Ltd Company Information
  9. 7.2.2 Wockhardt Ltd Business Overview
  10. 7.2.3 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  12. 7.2.5 Wockhardt Ltd Recent Developments
  13. 7.3 Therapeutic Systems Research Laboratories Inc
  14. 7.3.1 Therapeutic Systems Research Laboratories Inc Company Information
  15. 7.3.2 Therapeutic Systems Research Laboratories Inc Business Overview
  16. 7.3.3 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  18. 7.3.5 Therapeutic Systems Research Laboratories Inc Recent Developments
  19. 7.4 TGV-Inhalonix Inc
  20. 7.4.1 TGV-Inhalonix Inc Company Information
  21. 7.4.2 TGV-Inhalonix Inc Business Overview
  22. 7.4.3 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  24. 7.4.5 TGV-Inhalonix Inc Recent Developments
  25. 7.5 Roivant Sciences Ltd
  26. 7.5.1 Roivant Sciences Ltd Company Information
  27. 7.5.2 Roivant Sciences Ltd Business Overview
  28. 7.5.3 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  30. 7.5.5 Roivant Sciences Ltd Recent Developments
  31. 7.6 Lysimmune BioScience
  32. 7.6.1 Lysimmune BioScience Company Information
  33. 7.6.2 Lysimmune BioScience Business Overview
  34. 7.6.3 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  36. 7.6.5 Lysimmune BioScience Recent Developments
  37. 7.7 Destiny Pharma Plc
  38. 7.7.1 Destiny Pharma Plc Company Information
  39. 7.7.2 Destiny Pharma Plc Business Overview
  40. 7.7.3 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  42. 7.7.5 Destiny Pharma Plc Recent Developments
  43. 7.8 Debiopharm International SA
  44. 7.8.1 Debiopharm International SA Company Information
  45. 7.8.2 Debiopharm International SA Business Overview
  46. 7.8.3 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  48. 7.8.5 Debiopharm International SA Recent Developments
  49. 7.9 CrystalGenomics Inc
  50. 7.9.1 CrystalGenomics Inc Company Information
  51. 7.9.2 CrystalGenomics Inc Business Overview
  52. 7.9.3 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  54. 7.9.5 CrystalGenomics Inc Recent Developments
  55. 7.10 Amprologix Ltd
  56. 7.10.1 Amprologix Ltd Company Information
  57. 7.10.2 Amprologix Ltd Business Overview
  58. 7.10.3 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  60. 7.10.5 Amprologix Ltd Recent Developments
8 North America
  1. 8.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type
  2. 8.1.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021-2032)
  3. 8.1.2 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2032)
  4. 8.1.3 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Type (2021-2032)
  5. 8.2 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application
  6. 8.2.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021-2032)
  7. 8.2.2 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2032)
  8. 8.2.3 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Application (2021-2032)
  9. 8.3 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country
  10. 8.3.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type
  2. 9.1.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021-2032)
  3. 9.1.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2032)
  4. 9.1.3 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Type (2021-2032)
  5. 9.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application
  6. 9.2.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021-2032)
  7. 9.2.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2032)
  8. 9.2.3 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Application (2021-2032)
  9. 9.3 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country
  10. 9.3.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type
  2. 10.1.1 China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021-2032)
  3. 10.1.2 China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2032)
  4. 10.1.3 China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Type (2021-2032)
  5. 10.2 China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application
  6. 10.2.1 China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021-2032)
  7. 10.2.2 China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2032)
  8. 10.2.3 China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type
  2. 11.1.1 Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021-2032)
  3. 11.1.2 Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2032)
  4. 11.1.3 Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Type (2021-2032)
  5. 11.2 Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application
  6. 11.2.1 Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021-2032)
  7. 11.2.2 Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2032)
  8. 11.2.3 Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Application (2021-2032)
  9. 11.3 Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country
  10. 11.3.1 Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type
  2. 12.1.1 SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Type (2021-2032)
  5. 12.2 SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application
  6. 12.2.1 SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Application (2021-2032)
  9. 12.3 SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country
  10. 12.3.1 SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Value Chain Analysis
  2. 13.1.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Production Mode & Process
  6. 13.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Distributors
  9. 13.2.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst